PriceTargets.com logo

iCAD - ICAD Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.55 As of 11/20/2024 01:00 AM ET
▼ -0.02 (-1.28%)

This chart shows the closing price for ICAD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New iCAD Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ICAD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICAD

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for iCAD in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.55.

This chart shows the closing price for ICAD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in iCAD. This rating has held steady since March 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/19/2023Lake Street CapitalBoost Target$2.50 ➝ $5.00
4/13/2023JMP SecuritiesLower TargetOutperform$7.00 ➝ $4.00
4/4/2023OppenheimerLower TargetOutperform$5.00 ➝ $4.00
3/29/2023Lake Street CapitalLower TargetBuy$5.00 ➝ $2.50
3/29/2023BTIG ResearchLower TargetBuy$4.00 ➝ $3.00
11/16/2022BTIG ResearchLower Target$4.00
11/11/2022Lake Street CapitalLower Target$8.00 ➝ $5.00
9/1/2022JMP SecuritiesLower TargetMarket Outperform$13.00 ➝ $7.00
8/15/2022Craig HallumLower Target$6.00
8/15/2022BTIG ResearchLower Target$6.00
8/11/2022Lake Street CapitalLower TargetBuy$13.00 ➝ $8.00
6/24/2022BTIG ResearchLower TargetBuy$10.00 ➝ $8.00
3/1/2022Lake Street CapitalLower Target$22.00 ➝ $13.00
1/18/2022GuggenheimDowngradeBuy ➝ Neutral
1/5/2022JMP SecuritiesReiterated RatingBuy$13.00
1/5/2022OppenheimerLower TargetOutperform$22.00 ➝ $16.00
1/5/2022Lake Street CapitalLower TargetBuy ➝ Buy$25.00 ➝ $22.00
11/10/2021BTIG ResearchReiterated RatingBuy$24.00
11/10/2021JMP SecuritiesReiterated RatingBuy$22.00 ➝ $18.00
8/30/2021OppenheimerReiterated RatingBuy$24.00
4/22/2021GuggenheimInitiated CoverageBuy$24.00
3/23/2021BTIG ResearchInitiated CoverageBuy$25.00
2/26/2021B. RileyBoost TargetBuy$18.00 ➝ $23.00
2/25/2021OppenheimerInitiated CoverageOutperform$27.00
2/25/2021Craig HallumBoost TargetBuy$15.00 ➝ $22.00
2/25/2021Lake Street CapitalBoost TargetBuy$17.00 ➝ $21.00
1/28/2021Cantor FitzgeraldInitiated CoverageOverweight$19.00
12/15/2020B. RileyBoost TargetBuy$15.00 ➝ $18.00
12/11/2020Lake Street CapitalBoost TargetBuy$14.00 ➝ $17.00
12/3/2020B. RileyInitiated CoverageBuy$15.00
2/13/2020Craig HallumBoost TargetBuy$9.00 ➝ $15.00
2/5/2020JMP SecuritiesInitiated CoverageOutperform$15.00
1/9/2020Lake Street CapitalInitiated CoverageBuy$14.00
12/20/2019Dougherty & CoInitiated CoverageBuy$10.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 4 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 4 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

iCAD logo
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Read More

Today's Range

Now: $1.55
Low: $1.47
High: $1.57

50 Day Range

MA: $1.72
Low: $1.39
High: $2.40

52 Week Range

Now: $1.55
Low: $1.18
High: $2.65

Volume

365,136 shs

Average Volume

265,472 shs

Market Capitalization

$41.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47

Frequently Asked Questions

What sell-side analysts currently cover shares of iCAD?

The following Wall Street research analysts have issued stock ratings on iCAD in the last year: StockNews.com.
View the latest analyst ratings for ICAD.

What is the current price target for iCAD?

0 Wall Street analysts have set twelve-month price targets for iCAD in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for iCAD in the next year.
View the latest price targets for ICAD.

What is the current consensus analyst rating for iCAD?

iCAD currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ICAD.

What other companies compete with iCAD?

Other companies that are similar to iCAD include PolyPid, BrainsWay, Alpha Tau Medical, Lakeland Industries and Nevro. Learn More about companies similar to iCAD.

How do I contact iCAD's investor relations team?

iCAD's physical mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company's listed phone number is (603) 882-5200 and its investor relations email address is [email protected]. The official website for iCAD is www.icadmed.com. Learn More about contacing iCAD investor relations.